Platelet BioGenesis Leadership

As co-founder and chief operating officer of Platelet BioGenesis, I have built the world’s leading cell therapy platform leveraging platelet biology. I have raised more than $100 million in funding and built a team of 50+ dedicated scientists and executives.

I’m driven by the complex challenges of building teams to develop novel first-in-class products, such as engineered cell therapies, and have experience developing products derived from induced pluripotent stem cells (iPSCs). I'm accomplished at clearly communicating complex concepts and have won numerous business pitch competitions locally and globally.

The combination of my operating and venture capital experience enables me to offer in-depth insight into the potential of emerging technologies balanced by my real-world experience into the challenges of commercialization.



Earlier in my career, I held a variety of board-level and senior positions in the clean technology field, helping a variety of renewable energy companies scale. Prior to that I was a senior analyst of M&A and Business Development at JPMorgan and other asset management firms.

As co-founder and chief operating officer of Platelet BioGenesis, I have built the world’s leading cell therapy platform leveraging platelet biology. I have raised more than $100 million in funding and built a team of 50+ dedicated scientists and executives.

I’m driven by the complex challenges of building teams to develop novel first-in-class products, such as engineered cell therapies, and have experience developing products derived from induced pluripotent stem cells (iPSCs). I'm accomplished at clearly communicating complex concepts and have won numerous business pitch competitions locally and globally.

The combination of my operating and venture capital experience enables me to offer in-depth insight into the potential of emerging technologies balanced by my real-world experience into the challenges of commercialization.



Earlier in my career, I held a variety of board-level and senior positions in the clean technology field, helping a variety of renewable energy companies scale. Prior to that I was a senior analyst of M&A and Business Development at JPMorgan and other asset management firms.

As co-founder and chief operating officer of Platelet BioGenesis, I have built the world’s leading cell therapy platform leveraging platelet biology. I have raised more than $100 million in funding and built a team of 50+ dedicated scientists and executives.

I’m driven by the complex challenges of building teams to develop novel first-in-class products, such as engineered cell therapies, and have experience developing products derived from induced pluripotent stem cells (iPSCs). I'm accomplished at clearly communicating complex concepts and have won numerous business pitch competitions locally and globally.

The combination of my operating and venture capital experience enables me to offer in-depth insight into the potential of emerging technologies balanced by my real-world experience into the challenges of commercialization.



Earlier in my career, I held a variety of board-level and senior positions in the clean technology field, helping a variety of renewable energy companies scale. Prior to that I was a senior analyst of M&A and Business Development at JPMorgan and other asset management firms.